The safety and efficacy of Dificid were demonstrated in two trials that included 564 patients with CDAD that compared Dificid with vancomycin, a common antibiotic used to treat CDAD. The clinical response was similar in the Dificid group compared with the vancomycin group in both studies. In some patients with CDAD, symptoms can return. In the trials, a greater number of patients treated with Dificid had a sustained cure three weeks after treatment ended compared with patients treated with vancomycin.
Dificid was developed by San Diego-based Optimer Pharmaceuticals.
Read the FDA news release about Dificid.
Related Articles on C. Difficile:
10 Steps for Preventing C. Diff Outbreaks
C. Diff Increases Risk of Death 6-Fold in Inflammatory Bowel Disease Patients
6 Patients at New York Hospital Have C. Diff
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.